COVID-19 Antiviral Survey

This survey is to assess the healthcare facilities in Illinois and their interest to receive, store, and dispense antivirals for COVID-19. Please review the questions below and indicate interest in participating in this effort. IDPH appreciates your participation in this survey to inform allocation and distribution strategies for these medications. PFIZER PAXLOVID The U.S. Food and Drug Administration has issued an EUA for the emergency use of the unapproved PAXLOVID which includes nirmatrelvir, a SARS-CoV-2 main protease (Mpro: also referred to as 3CLpro or nsp5 protease) inhibitor, and ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor, for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. MERCK MOLNUPIRAVIR Oral COVID-19 Antiviral Medicine, pending EUA in the US, for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. Molnupiravir is in capsule form, packaged as individual courses. ASTRAZENECA EVUSHELD (AZ7442) Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorized in the US for COVID-19 pre-exposure prophylaxis and the only COVID-19 antibody delivered as an intramuscular dose (150mg tixagevimab and 150mg cilgavimab). EVUSHELD is supplied as a single carton (NDC 0310-7442-02) containing 1 single-dose vial of tixagevimab injection and 1 single-dose vial of cilgavimab injection. Unopened vials of tixagevimab and cilgavimab must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Vials must not be frozen or shaken.